Floatz logo

L19IL2/L19TNF

Kaposi Sarcoma

Philogen S.p.A.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Kaposi Sarcoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B
Gdc-0449
National Cancer Institute (NCI)
Phase 1/2CCC
Sgn-30
Phase 1/2CCC
cd146/her2 car-t cells
Essen Biotech
Phase 1/2CCC
Pembrolizumab
Memorial Sloan Kettering Cancer Center
Phase 1CC

View all 14 →

Same molecule, other indications

L19IL2/L19TNF is also rated in:

skin basal cell carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
squamous cell carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
cutaneous neuroendocrine carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →